NAGE PE Ratio & Valuation,Is NAGE Overvalued

NAGE Relative Valuation

NAGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAGE is overvalued; if below, it's undervalued.

Historical Valuation

Niagen Bioscience Inc (NAGE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 27.33 is considered Undervalued compared with the five-year average of 58.34. The fair price of Niagen Bioscience Inc (NAGE) is between 7.21 to 17.26 according to relative valuation methord. Compared to the current price of 6.57 USD , Niagen Bioscience Inc is Undervalued By 8.82%.

Relative Value

Fair Zone

7.21-17.26

Current Price：6.57

8.82%

Undervalued

27.33

17.93

EV/EBITDA

Niagen Bioscience Inc. (NAGE) has a current EV/EBITDA of 17.93. The 5-year average EV/EBITDA is 37.08. The thresholds are as follows: Strongly Undervalued below 7.76, Undervalued between 7.76 and 22.42, Fairly Valued between 51.73 and 22.42, Overvalued between 51.73 and 66.39, and Strongly Overvalued above 66.39. The current Forward EV/EBITDA of 17.93 falls within the Undervalued range.

26.58

EV/EBIT

Niagen Bioscience Inc. (NAGE) has a current EV/EBIT of 26.58. The 5-year average EV/EBIT is 54.03. The thresholds are as follows: Strongly Undervalued below 13.07, Undervalued between 13.07 and 33.55, Fairly Valued between 74.51 and 33.55, Overvalued between 74.51 and 94.99, and Strongly Overvalued above 94.99. The current Forward EV/EBIT of 26.58 falls within the Undervalued range.

3.45

Niagen Bioscience Inc. (NAGE) has a current PS of 3.45. The 5-year average PS is 5.10. The thresholds are as follows: Strongly Undervalued below 2.58, Undervalued between 2.58 and 3.84, Fairly Valued between 6.36 and 3.84, Overvalued between 6.36 and 7.62, and Strongly Overvalued above 7.62. The current Forward PS of 3.45 falls within the Undervalued range.

16.57

P/OCF

Niagen Bioscience Inc. (NAGE) has a current P/OCF of 16.57. The 5-year average P/OCF is 34.98. The thresholds are as follows: Strongly Undervalued below 6.19, Undervalued between 6.19 and 20.58, Fairly Valued between 49.37 and 20.58, Overvalued between 49.37 and 63.77, and Strongly Overvalued above 63.77. The current Forward P/OCF of 16.57 falls within the Undervalued range.

20.06

P/FCF

Niagen Bioscience Inc. (NAGE) has a current P/FCF of 20.06. The 5-year average P/FCF is 50.42. The thresholds are as follows: Strongly Undervalued below -16.06, Undervalued between -16.06 and 17.18, Fairly Valued between 83.66 and 17.18, Overvalued between 83.66 and 116.90, and Strongly Overvalued above 116.90. The current Forward P/FCF of 20.06 falls within the Historic Trend Line -Fairly Valued range.

Niagen Bioscience Inc (NAGE) has a current Price-to-Book (P/B) ratio of 7.07. Compared to its 3-year average P/B ratio of 11.42 , the current P/B ratio is approximately -38.09% higher. Relative to its 5-year average P/B ratio of 11.42, the current P/B ratio is about -38.09% higher. Niagen Bioscience Inc (NAGE) has a Forward Free Cash Flow (FCF) yield of approximately 4.22%. Compared to its 3-year average FCF yield of 2.91%, the current FCF yield is approximately 45.14% lower. Relative to its 5-year average FCF yield of 2.91% , the current FCF yield is about 45.14% lower.

7.07

P/B

Median3y

11.42

Median5y

11.42

4.22

FCF Yield

Median3y

2.91

Median5y

2.91

Competitors Valuation Multiple

The average P/S ratio for NAGE's competitors is 1.50, providing a benchmark for relative valuation. Niagen Bioscience Inc Corp (NAGE) exhibits a P/S ratio of 3.45, which is 129.83% above the industry average. Given its robust revenue growth of 32.86%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NAGE increased by 20.07% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 7.34 to 13.47.

The secondary factor is the Revenue Growth, contributed 32.86%to the performance.

Overall, the performance of NAGE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

32.86%

25.58M → 33.99M

Revenue Growth

83.51%

7.34 → 13.47

Margin Expansion

-96.30%

719.13 → 26.61

P/E Change

20.07%

5.63 → 6.76

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Niagen Bioscience Inc (NAGE) currently overvalued or undervalued?

What is Niagen Bioscience Inc (NAGE) fair value?

NAGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Niagen Bioscience Inc (NAGE) is between 7.21 to 17.26 according to relative valuation methord.

How does NAGE's valuation metrics compare to the industry average?

What is the current P/B ratio for Niagen Bioscience Inc (NAGE) as of Jan 07 2026?

As of Jan 07 2026, Niagen Bioscience Inc (NAGE) has a P/B ratio of 7.07. This indicates that the market values NAGE at 7.07 times its book value.

What is the current FCF Yield for Niagen Bioscience Inc (NAGE) as of Jan 07 2026?

As of Jan 07 2026, Niagen Bioscience Inc (NAGE) has a FCF Yield of 4.22%. This means that for every dollar of Niagen Bioscience Inc’s market capitalization, the company generates 4.22 cents in free cash flow.

What is the current Forward P/E ratio for Niagen Bioscience Inc (NAGE) as of Jan 07 2026?

As of Jan 07 2026, Niagen Bioscience Inc (NAGE) has a Forward P/E ratio of 27.33. This means the market is willing to pay $27.33 for every dollar of Niagen Bioscience Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Niagen Bioscience Inc (NAGE) as of Jan 07 2026?

As of Jan 07 2026, Niagen Bioscience Inc (NAGE) has a Forward P/S ratio of 3.45. This means the market is valuing NAGE at $3.45 for every dollar of expected revenue over the next 12 months.

NAGE Valuation

Overview

Forecast

Valuation

Earnings